Health ❯ Healthcare ❯ Obesity

Weight Loss

Medications GLP-1 Medications GLP-1 Drugs Pharmaceuticals Mounjaro Weight Loss Drugs Weight Loss Injections Clinical Trials GLP-1 Agonists Semaglutide Long-term Effects Prescription Drugs Tirzepatide Bariatric Surgery Medication Dietary Recommendations Incretin Drugs Market Trends Orforglipron Weight-Loss Surgery Metabolic Health Medication Accessibility Public Awareness Campaigns Patient Outcomes Intervention Effectiveness Hormone Agonists GLP-1 Treatments Medication for Weight Loss Long-term Maintenance Medication Discontinuation Post-Treatment Effects Medication Risks Dietary Medications Retatrutide Zepbound Weight-loss Injections Patient Care Weight Loss Medications Injectable Medications GLP-1 Pill Obesity Drugs GLP-1 Receptor Agonists Behavioral Change Generic Medications Cancer Risk Reduction Interventions Clinical Studies Surgical Methods

India Braces for 50+ Semaglutide Generics as Patent Expires Friday

Sharp price cuts are expected alongside tighter oversight following new Indian safety advisories.

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

GLP-1 Era Hits the Mainstream With Super Bowl Ads as Costs Rise and Care Shifts to Maintenance

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

Lilly to Launch Late-Stage Trials of Amylin Obesity Drug After 20% Weight Loss in Mid-Stage Study

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss